Literature DB >> 35868545

Erythrodermic Psoriasis Following SARS-CoV-2 Infection.

A Fatima-Zahra1, G Basri2, S Nejjari2, S Chiheb2.   

Abstract

Entities:  

Year:  2022        PMID: 35868545      PMCID: PMC9296225          DOI: 10.1016/j.ad.2022.07.014

Source DB:  PubMed          Journal:  Actas Dermosifiliogr        ISSN: 0001-7310


× No keyword cloud information.
Dear Editor: Exacerbation of psoriasis during SARS-CoV-2 infection has been described in the literature. However, the occurrence of erythroderma remains a very rare manifestation with only a few cases worldwide.1, 2 We report a case of erythrodermic psoriasis following a moderate SARS-CoV-2 infection. The role of stress and the treatments used has been suggested but there is another hypothesis incriminating the virus itself directly.

Case report

A 55-year-old patient, followed for 3 years for localized plaque psoriasis, treated with dermocorticoids at the time of flare-ups, presented to the emergency room for a worsening of his psoriasis with the development of erythroderma. The clinical presentation occurred 10 days after a simple form of covid consisting of flu-like syndrome, myalgias, fever and cough. The patient was treated symptomatically with paracetamol and vitamin C, without recourse to synthetic anti-malarial drugs or oral corticosteroids. The general examination revealed a hemodynamically stable patient with a fever of 38 °C. The dermatological examination revealed a dry erythroderma (Fig. 1 ). The patient was hospitalized for 2 weeks and a symptomatic treatment based on dermocorticoids was started at the beginning and then a specific treatment with anti-interleukin 12/23 (Ustekinumab) was started after a general assessment not contraindicating its use.
Figure 1

Dry Erythroderma.

Dry Erythroderma. The evolution was marked by a beginning of improvement from the first injection of ustekinumab and a skin whitening 2 months after the second one.

Discussion

Erythrodermic psoriasis is a severe form of psoriasis. It may be a manifestation of unrecognized psoriasis or a complication of diagnosed psoriasis. Several factors have been implicated in the occurrence of this complication such as genetic mutation especially of CARD 14 gene, certain bacterial (streptococcal and staphylococcal) or viral (HIV, CMV and Epstein bar virus) infections and certain medications such us oral corticosteroids, synthetic antimalarials, beta-blockers, terbinafine, cyclins, and non-steroidal anti-inflammatory drugs. The occurrence of erythroderma in patients followed for psoriasis during covid-19 infection is a very rare event. To our knowledge, only two cases have been described in the literature. Ghalamkarpour was the first to report a case of psoriatic erythroderma 3 weeks after a mild form of covid-19 infection. In January 2022, Demiri reported a second case in a patient who presented with dry erythroderma 5 days after a moderate form of covid-19 infection. Several pathophysiological hypotheses may explain the link between covid-19 infection and the occurrence of this complication. Firstly, covid-19 infection is considered to be a stressful state for the body, leading to a decrease in immunity. However, stress alone cannot be considered as a directly responsible factor in the occurrence of posriasis erythroderma. Secondly, there is the aggravating influence of certain drugs used in the treatment of SARS-CoV-2 infection, in particular oral corticosteroids with a relapse effect and hydroxychloroquine, which is known to cause a dysregulation of epidermal transglutaminase, leading to keratinocyte hyperproliferation. A third hypothesis incriminates the SARS-CoV-2 virus as an aggravating factor in psoriasis thought the anti-viral immune response with increased production of pro-inflammatory cytokines such as interleukin 17, interleukin 23, interleukin 6, TNF alpha and INF alpha, the same being involved in the pathophysiology of psoriasis and especially the interferon gamma, implicated in the erythrodermic form. This hypothesis is supported by some published reports that have shown that psoriatic patients on biotherapies, such as anti-interleukin 17, developed fewer severe forms of covid-19 than those on topical therapy alone. There is also the role of Th2 type cytokines which are involved both in the anti-covid immune response and in the erythrodermic form of psoriasis. It also seems that such as streptococcus, the virus SARS-CoV-2 played by the spike protein present on its surface the role of superantigen which is supporting by cases of psoriasis exacerbation after covid-19 vaccination. In our patient, a coincidence cannot be formally eliminated but the hypothesis retained which would explain the appearance of this erythroderma is the infection by SARS-CoV-2, because of the temporal relation but also because he did not receive any of the treatments incriminated in the occurrence of this complication.

Author contributions

All authors contributed to the conduct of this work. All authors also state that they have read and approved the final version of the manuscript.

Funding

The authors did not receive any funding.

Conflicts of interest

The authors have no conflicts of interest to declare.
  10 in total

Review 1.  HIV-associated psoriasis: pathogenesis, clinical features, and management.

Authors:  Nilesh Morar; Saffron A Willis-Owen; Toby Maurer; Christopher B Bunker
Journal:  Lancet Infect Dis       Date:  2010-07       Impact factor: 25.071

2.  Analysis of Th1/Th2 response pattern for erythrodermic psoriasis.

Authors:  Ping Zhang; Hong-Xiang Chen; Yi-Qun Duan; Wei-Zhen Wang; Tian-Zhu Zhang; Jia-Wen Li; Ya-Ting Tu
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2014-08-19

3.  Serum interferon-gamma is a psoriasis severity and prognostic marker.

Authors:  Marwa A Abdallah; Mahmoud F Abdel-Hamid; Amr M Kotb; Elham A Mabrouk
Journal:  Cutis       Date:  2009-09

4.  Whole exome sequencing approach to childhood onset familial erythrodermic psoriasis unravels a novel mutation of CARD14 requiring unusual high doses of ustekinumab.

Authors:  S Signa; E Campione; M Rusmini; S Chiesa; A Grossi; A Omenetti; R Caorsi; G M Viglizzo; M Galluzzo; L Bianchi; M Talamonti; A Orlandi; A Martini; I Ceccherini; M Gattorno
Journal:  Pediatr Rheumatol Online J       Date:  2019-07-08       Impact factor: 3.054

5.  Superantigenic character of an insert unique to SARS-CoV-2 spike supported by skewed TCR repertoire in patients with hyperinflammation.

Authors:  Mary Hongying Cheng; She Zhang; Rebecca A Porritt; Magali Noval Rivas; Lisa Paschold; Edith Willscher; Mascha Binder; Moshe Arditi; Ivet Bahar
Journal:  Proc Natl Acad Sci U S A       Date:  2020-09-28       Impact factor: 11.205

6.  COVID-19 and helminth infection: Beyond the Th1/Th2 paradigm.

Authors:  Alberto E Paniz-Mondolfi; Juan David Ramírez; Lourdes A Delgado-Noguera; Alfonso J Rodriguez-Morales; Emilia M Sordillo
Journal:  PLoS Negl Trop Dis       Date:  2021-05-24

7.  [Erythrodermic psoriasis after COVID-19].

Authors:  Jeta Demiri; Miriam Abdo; Athanasios Tsianakas
Journal:  Hautarzt       Date:  2021-12-14       Impact factor: 0.751

8.  A case of severe psoriatic erythroderma with COVID-19.

Authors:  Fariba Ghalamkarpour; Mohammad Reza Pourani; Fahimeh Abdollahimajd; Omid Zargari
Journal:  J Dermatolog Treat       Date:  2020-08-04       Impact factor: 3.359

Review 9.  Drug-induced psoriasis: clinical perspectives.

Authors:  Deepak Mw Balak; Enes Hajdarbegovic
Journal:  Psoriasis (Auckl)       Date:  2017-12-07
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.